NCT07936162
Immune Reconstitution and Clinical Prognosis Following Umbilical Cord Blood Transplantation
StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Frequency of infection-related laboratory testing (blood culture, pathogen PCR, NGS)
Timeframe: 6 months post-transplant
Number of medication adjustments intended to accelerate immune reconstitution or enhance infection prophylaxis
Timeframe: 6 months post-transplant
Number of return visits
Timeframe: 6 months post-transplant
Secondary (10)
Frequency of infection-related laboratory testing (blood culture, pathogen PCR, NGS)
Number of medication adjustments intended to accelerate immune reconstitution or enhance infection prophylaxis
Number of return visits
Immune reconstitution status (quantity of T, B, NK cells and other immune subsets, and T cell clonal diversity)
Infection rate
Show 5 moreShow less
Incidence of chronic GVHD
Relapse rate
Survival
Hospitalization rate
Outpatient rate
Arms and interventions
Composite Immune Risk Score Stratification Notification GroupExperimental
Attending physicians will receive immune reconstitution risk stratification results of patients calculated by the composite immune risk score model to guide patient health monitoring.
Standard Care Control GroupNo intervention
No risk stratification results of patients from the composite immune risk score model will be provided to attending physicians. Patients receive standard routine care.
Behavioral: Composite Immune Risk Score Stratification Notification Group
Sites
1 site in 1 country
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeTianjin, China